4
Changes in Ownership
Axsome Therapeutics, Inc. Filed Acc 0001193125-26-174415
Chief Commercial Officer sold 7,500 shares at $182.42 ($1,368,150)
- Chief Commercial Officer acquired 7,500 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Maizel Ari · Chief Commercial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-04-22 | Exercise or conversion : show line 1 in the form 10b5-1 | +7,500 | $70.73 | $530,475 | 7,500 | D |
| 2026-04-22 | Sale : show line 2 in the form 10b5-1 | −7,500 | $182.42 | $1,368,150 | 0 | D |
| Open-market sales · 7,500 sh · avg $182.42 · $1,368,150 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-04-22 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (Right to Buy) | −7,500 | 23,710 | D |
Loading xslF345X06/ownership.xml…